Aragon Pharmaceuticals, Inc. (Acquired by Johnson & Johnson)

17 articles with Aragon Pharmaceuticals, Inc. (Acquired by Johnson & Johnson)

• 

  A New $550 Million Life Sciences Venture Capital Fund is in Town

  6/3/2021

  venBio Global Strategic Fund IV will invest primarily in drug companies focused on developing therapies for unmet medical needs.
• 

  Alder CEO Is Stepping Down

  3/21/2018

  Alder BioPharmaceuticals announced that Randall Schatzman, the company’s president, chief executive officer and director, will be stepping down.

• Johnson & Johnson Completes Acquisition of Aragon Pharmaceuticals, Inc.

  8/20/2013

• Johnson & Johnson to Buy Aragon Pharmaceuticals, Inc. for Up to $1 Billion

  6/17/2013

• Aragon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase I Study of ARN-810 in Estrogen Receptor Positive Breast Cancer

  4/4/2013

• Aragon Pharmaceuticals, Inc. Announces Key Strategic Hire

  2/11/2013

• Aragon Pharmaceuticals, Inc. Wins Key Legal Ruling Against Medivation, Inc.

  1/4/2013

• Aragon Pharmaceuticals, Inc. Snags $50 Million Series D

  10/4/2012

• Aragon Pharmaceuticals, Inc. Raises $50 Million

  10/1/2012

• Aragon Pharmaceuticals, Inc. Announces Clinical Results from Ongoing Phase II Trial Confirming Robust Anti-Tumor Activity and Tolerability of ARN-509 in Three Different Patient Populations of Castration Resistant Prostate Cancer

  10/1/2012

• Aragon Pharmaceuticals, Inc. Announces Appointment of Faheem Hasnain as Independent Director

  8/28/2012

• Aragon Pharmaceuticals, Inc. Nabs $42 Million, Targets Hormone-Driven Cancers

  3/6/2012

• Aragon Pharmaceuticals, Inc. to Present at the 10th Annual Biotechnology Industry Organization (BIO) Investor Forum on October 26

  10/20/2011

• Aragon Pharmaceuticals, Inc. Doses First Patient in Phase 1/2 Clinical Trial of ARN-509 for Castration-Resistant Prostate Cancer

  8/9/2010

• Aragon Pharmaceuticals, Inc. Appoints Richard A. Heyman CEO

  8/2/2010

• Aragon Pharmaceuticals, Inc. Secures $22 Million in Series B Financing

  4/22/2010

• Aragon Pharmaceuticals Announces $8 Million Series A Financing

  5/20/2009